This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront cystectomy.
▪ Inclusion Criteria
Willing and able to provide informed consent
Age ≥18 years old
Eligible to receive standard of care systemic neoadjuvant therapy
Patients under 18 years old. Considering the minimal incidence of bladder cancer among the pediatric population, children are not eligible for this study.
Not willing or unable to give informed consent.
Clinical or pathological evidence of metastatic disease, including, non-regional lymph nodes, visceral lesions, and bone lesions.
Significant hepatic impairment (Serum bilirubin > 1.5x upper limit of normal).